Annual Shareholders Equity
$500.76 M
-$77.31 M-13.37%
December 31, 2023
Summary
- As of February 7, 2025, RNA annual stockholders equity is $500.76 million, with the most recent change of -$77.31 million (-13.37%) on December 31, 2023.
- During the last 3 years, RNA annual shareholders equity has risen by +$194.54 million (+63.53%).
- RNA annual shareholders equity is now -13.37% below its all-time high of $578.08 million, reached on December 31, 2022.
Performance
RNA Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Shareholders Equity
$1.50 B
+$282.34 M+23.12%
September 1, 2024
Summary
- As of February 7, 2025, RNA quarterly stockholders equity is $1.50 billion, with the most recent change of +$282.34 million (+23.12%) on September 1, 2024.
- Over the past year, RNA quarterly shareholders equity has increased by +$985.91 million (+190.53%).
- RNA quarterly shareholders equity is now at all-time high.
Performance
RNA Quarterly Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Shareholders Equity Formula
Shareholders Equity = Total Assets − Total Liabilities
RNA Shareholders Equity Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -13.4% | +190.5% |
| 3 y3 years | +63.5% | +280.7% |
| 5 y5 years | +1317.5% | - |
RNA Shareholders Equity Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -13.4% | +31.3% | at high | +301.6% |
| 5 y | 5-year | -13.4% | +866.2% | at high | +2400.3% |
| alltime | all time | -13.4% | +866.2% | at high | +2400.3% |
Avidity Biosciences Shareholders Equity History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $1.50 B(+23.1%) |
| Jun 2024 | - | $1.22 B(+47.0%) |
| Mar 2024 | - | $830.90 M(+65.9%) |
| Dec 2023 | $500.76 M(-13.4%) | $500.76 M(-3.2%) |
| Sep 2023 | - | $517.47 M(-7.5%) |
| Jun 2023 | - | $559.18 M(+0.0%) |
| Mar 2023 | - | $558.91 M(-3.3%) |
| Dec 2022 | $578.08 M | $578.08 M(+53.3%) |
| Sep 2022 | - | $376.98 M(+0.7%) |
| Jun 2022 | - | $374.35 M(-0.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $375.71 M(-1.5%) |
| Dec 2021 | $381.43 M(+24.6%) | $381.43 M(-3.4%) |
| Sep 2021 | - | $394.88 M(+49.3%) |
| Jun 2021 | - | $264.48 M(-7.6%) |
| Mar 2021 | - | $286.12 M(-6.6%) |
| Dec 2020 | $306.22 M(-568.5%) | $306.22 M(-4.4%) |
| Sep 2020 | - | $320.16 M(-3.1%) |
| Jun 2020 | - | $330.30 M(+400.4%) |
| Mar 2020 | - | $66.00 M(-201.0%) |
| Dec 2019 | -$65.36 M(+58.9%) | -$65.36 M |
| Dec 2018 | -$41.13 M | - |
FAQ
- What is Avidity Biosciences annual stockholders equity?
- What is the all time high annual shareholders equity for Avidity Biosciences?
- What is Avidity Biosciences annual shareholders equity year-on-year change?
- What is Avidity Biosciences quarterly stockholders equity?
- What is the all time high quarterly shareholders equity for Avidity Biosciences?
- What is Avidity Biosciences quarterly shareholders equity year-on-year change?
What is Avidity Biosciences annual stockholders equity?
The current annual shareholders equity of RNA is $500.76 M
What is the all time high annual shareholders equity for Avidity Biosciences?
Avidity Biosciences all-time high annual stockholders equity is $578.08 M
What is Avidity Biosciences annual shareholders equity year-on-year change?
Over the past year, RNA annual stockholders equity has changed by -$77.31 M (-13.37%)
What is Avidity Biosciences quarterly stockholders equity?
The current quarterly shareholders equity of RNA is $1.50 B
What is the all time high quarterly shareholders equity for Avidity Biosciences?
Avidity Biosciences all-time high quarterly stockholders equity is $1.50 B
What is Avidity Biosciences quarterly shareholders equity year-on-year change?
Over the past year, RNA quarterly stockholders equity has changed by +$985.91 M (+190.53%)